ERBB2 and breast cancer: This study focuses on understanding how ITGβ3 regulates EMT and its impact on Hedgehog signaling and examines whether targeting ITGβ3 with cilengitide can suppress EMT and Hedgehog pathway activity, thereby potentially improving the treatment response and overcoming the resistance of patients with trastuzumab-resistant HER2-positive breast cancer.